$CL

Colgate-Palmolive (NYSE: CL) awards stock, options to growth chief

Colgate-Palmolive (CL) granted its Chief Growth Officer, John Hazlin, 27,042 stock options and 3,908 restricted stock units on September 16, 2026. The options have an exercise price of $87.02 and expire in 2036, vesting in thirds. The RSUs vest in equal thirds over three years. Hazlin now holds 27,021 shares directly and 5,513 indirectly through the company's 401(k) plan.

Original reporting
Published Sep 18, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CL
Neutral
high confidence
Mentioned
$CL
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLNeutralLow
01

Why it matters

The compensation grant is routine and unlikely to move the stock.

02

Market read

Limited relevance; primarily an insider compensation disclosure.

03

What to watch

Potential future dilution if options are exercised.

Relevance 4/10Novelty 3/10Timing: September 16, 2026

Background

The article reports a Form 4 filing detailing equity awards to Colgate-Palmolive's Chief Growth Officer.

Company-level read

Ticker impact

$CLNeutralHigh confidence
Context

Chief Growth Officer John Hazlin received stock options for 27,042 shares and 3,908 RSUs on Sep 16, 2026.

Expected impact

No significant move expected.

Evidence & confidence

Grant size is small relative to market cap; typical for executive compensation and unlikely to affect share price.

Market effects

None

None

None

Counterpoint

Even small grants can signal confidence in growth strategy.

Key entities

  • Colgate-Palmolive

    Consumer goods company (NYSE: CL).

  • John Hazlin

    Chief Growth Officer receiving the awards.

Related articles

$CLMed

Piper Sandler cuts Colgate-Palmolive stock price target on cost pressures

Piper Sandler reduced its price target for Colgate-Palmolive (CL) to $95 from $98, citing cost pressures from elevated oil prices and inventory headwinds. The firm maintained an Overweight rating and a 2026 EPS estimate of $3.85, but lowered its 2027 EPS estimate to $4.12 from $4.23. CL trades at $87.47 with a P/E ratio of 34.6 and a gross profit margin of 60%. Other analysts have maintained positive outlooks, with RBC and UBS setting higher price targets.

$CLMedAI 8/10

Colgate-Palmolive Explores Sale Of Softsoap, Irish Spring, Speed Stick Brands: Report

Colgate-Palmolive (CL) is exploring the sale of brands like Softsoap, Irish Spring, and Speed Stick, potentially fetching over $1 billion. The company is working with Goldman Sachs (GS) on the divestiture. Personal care accounted for 17% of CL's 2025 net sales, which totaled $20.38 billion. The move is part of a broader productivity and restructuring program aimed at generating annual pre-tax savings of $200 million to $300 million by 2028.

$CLMedAI 8/10

Colgate-Palmolive reportedly weighs US$1B personal care offload.

Colgate-Palmolive is reportedly considering the sale of select mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, for over $1 billion. The company is working with Goldman Sachs on the potential divestment to focus on higher-margin businesses amid North American competition. Personal care accounted for 17% of its 2025 net sales of $20.38 billion.

$CLMed

CL Stock Alert: Colgate-Palmolive Reportedly Considers $1 Billion Brand Sale

Colgate-Palmolive (CL) is reportedly exploring the sale of non-core personal care brands, valued at over $1 billion, with Goldman Sachs' advisory. The move aims to reallocate capital toward higher-growth segments. CL shares are down 12% year-to-date, trading below major moving averages, but offer a 2.44% dividend yield. Institutional investors remain bullish, and the consensus rating is 'Moderate Buy' with a mean price target of $160.

$CLMedAI 8/10

Colgate-Palmolive Seeks Value Through Portfolio Reshaping

Colgate-Palmolive (NYSE:CL) is exploring the sale of mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, potentially generating over $1 billion. The move aims to simplify its portfolio and focus on higher-growth areas like oral care and pet nutrition, amid competitive pressure in North America. The company reported a 4.9% increase in net sales, but organic sales in North America declined 3%. Proceeds could be used for debt reduction, share repurchases, or acquisi